Genetic immunization

• US 5,830,876 A
• Filed: 05/30/1995
• Issued: 11/03/1998
• Est. Priority Date: 01/26/1993
• Status: Expired due to Term

• Current Assignee: The Wistar Institute, Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Original Assignee: The Wistar Institute, Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: Wang, Bin, Weiner, David B., Williams, William V.
• Primary Examiner(s): Elliott, George G.
• Assistant Examiner(s): RAILEY, JOHNNY F
• Application Number:
  US08/453,349
• Time in Patent Office: 1,253 Days
• Field of Search: 435/320.1, 424/93.1, 424/93.2, 424/93.21, 424/278.1, 514/44, 514/615, 514/818
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• CPC Class Codes: C12N 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
• CPC Class Codes: Y10S 435/975 Kit

Abstract

A method of immunizing an individual against pathogen is disclosed. Also disclosed is a method of treating an individual who has a hyperproliferative disease, or of treating an individual who is infected by a pathogen. Specifically, the individual is injected with bupivacaine along with DNA in an expressible form, the DNA encoding an antigen. The encoded antigen can be from a protein from the pathogen or from a protein associated with the hyperproliferative disease.

Claims

1. A method of immunizing an individual against a pathogen comprising the steps of:

injecting into skeletal muscle tissue of said individual at a site on said individual'"'"'s body, bupivacaine and a DNA molecule that comprises a DNA sequence that encodes an antigen from said pathogen, said DNA sequence operatively linked to regulatory sequences which control the expression of said DNA sequence;

wherein said DNA molecule is taken up by cells in said skeletal muscle tissue, said DNA sequence is expressed in said cells and a protective immune response is generated against said antigen.

2. The method of claim 1 wherein said pathogen is an intracellular pathogen.

3. The method of claim 1 wherein said pathogen is a virus.

4. The method of claim 1 wherein said pathogen is a virus selected from the group consisting of:

human T cell leukemia virus, HTLV;

influenza virus;

hepatitis A virus;

hepatitis B virus;

hepatitis C virus;

human papilloma virus, HPV;

Herpes simplex 1 virus, HSV1;

Herpes simplex 2 virus, HSV2;

Cytomegalovirus, CMV;

Epstein-Barr virus, EBR;

rhinovirus; and

, coronavirus.

5. The method of claim 1 wherein said pathogen is Herpes simplex 2 virus, HSV2.

6. The method of claim 1 wherein said pathogen is Hepatitis B virus, HBV.

7. The method of claim 1 wherein said pathogen is human T cell leukemia virus, HTLV.

8. A method of treating an individual who has a hyperproliferative disease comprising:

injecting into skeletal muscle tissue of said individual at a site on said individual'"'"'s body, bupivacaine and a DNA molecule that comprises a DNA sequence that encodes a hyperproliferative disease-associated protein operatively linked to regulatory sequences;

wherein said DNA molecule is taken up by cells in said skeletal muscle tissue, said DNA sequence is expressed in said cells, and a therapeutically effective immune response is generated against said hyperproliferative disease-associated protein, said immune response being directed at hyperproliferating cells expressing said hyperproliferative disease-associated protein.

9. The method of claim 8 wherein said hyperproliferative disease is cancer.

10. The method of claim 8 wherein said hyperproliferative disease is a lymphoma.

11. The method of claim 8 wherein said hyperproliferative disease is T cell lymphoma and said hyperproliferative disease-associated protein is a T cell antigen.

12. The method of claim 8 wherein said hyperproliferative disease is T cell lymphoma and said DNA sequence encodes a variable region of a T cell receptor.

13. The method of claim 8 wherein said hyperproliferative disease is a melanoma.

14. A method of treating an individual who is infected by a pathogen comprising:

injecting into skeletal muscle tissue of said individual at a site on said individual'"'"'s body, bupivacaine and a DNA molecule that comprises a DNA sequence that encodes an antigen from said pathogen, said DNA sequence operatively linked to regulatory sequences which control the expression of said DNA sequence;

wherein said DNA molecule is taken up by cells in said skeletal muscle tissue, said DNA sequence is expressed in said cells and a therapeutically effective immune response is generated.

15. The method of claim 14 wherein said pathogen is an intracellular pathogen.

16. The method of claim 14 wherein said pathogen is a virus.

17. The method of claim 14 wherein said pathogen is human immunodeficiency virus HIV.